{"id":1196,"date":"2024-01-17T13:59:46","date_gmt":"2024-01-17T13:59:46","guid":{"rendered":"https:\/\/www.the-nash-education-program.com\/?page_id=1196"},"modified":"2024-01-17T13:59:46","modified_gmt":"2024-01-17T13:59:46","slug":"quienes-estan-en-riesgo-de-padecer-nash","status":"publish","type":"page","link":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/","title":{"rendered":"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH?"},"content":{"rendered":"\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/obesity.png\" alt=\"\"\/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">PERSONAS CON OBESIDAD<\/h2>\n\n\n\n<p>Tanto NASH como NAFLD tienen un alto predominio en las poblaciones que padecen obesidad, pero la cifras exactas a\u00fan son dif\u00edciles de estimar. Una investigaci\u00f3n que analiza 12 estudios observacionales y transversales, la cual incluye a 1620 pacientes en total con obesidad severa (IMC&gt;40), demostr\u00f3 que el 91 % ten\u00eda NAFLD (rango: 85-98 %) y el 37 % ten\u00eda NASH (rango: 24-98 %).<sup>1<\/sup><\/p>\n\n\n\n<p>Otro estudio citado en las Gu\u00edas de Pr\u00e1ctica 2018 de la Asociaci\u00f3n Estadounidense para el Estudio de Enfermedades Hep\u00e1ticas (American Association for the Study of Liver Diseases, AASLD), indic\u00f3 que el 80.2&nbsp;% de las personas con un IMC &gt; 35mg\/m<sup>2<\/sup>&nbsp;ten\u00eda la enfermedad del h\u00edgado relacionada con la obesidad (esteatosis, o NASH o fibrosis).<sup>2-3<\/sup><\/p>\n\n\n\n<p><strong>NAFLD: 70% o m\u00e1s<sup>4<br><\/sup><\/strong><strong>NASH: 25-30%<sup>5<\/sup><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">PERSPECTIVAS<\/h2>\n\n\n\n<p>Durante los \u00faltimos 30 a\u00f1os, la obesidad alcanz\u00f3 proporciones epid\u00e9micas, y su predominio contin\u00faa aumentando. De acuerdo con la Organizaci\u00f3n para la Cooperaci\u00f3n y el Desarrollo Econ\u00f3micos (OCDE), el 47 % de los adultos en los Estados Unidos padecer\u00e1 obesidad antes de 2030, en comparaci\u00f3n con el 37.7 % en 2014. Esto representa un aumento del 25 % en la obesidad antes de 2030.<sup>6<\/sup><\/p>\n\n\n\n<figure class=\"wp-block-image\"><img decoding=\"async\" src=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/diabetes.png\" alt=\"\"\/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\">PERSONAS CON DIABETES TIPO 2<\/h2>\n\n\n\n<p>M\u00e1s de 500&nbsp;millones de personas se ven afectadas por la diabetes tipo&nbsp;2 en todo el mundo.<sup>7<\/sup>&nbsp;De acuerdo con varios estudios y las Gu\u00edas de Pr\u00e1ctica de la AASLD, alrededor de un tercio a dos tercios de los pacientes diab\u00e9ticos tiene NAFLD.<sup>2<\/sup><\/p>\n\n\n\n<p><strong>NAFLD<\/strong><strong>: 33&nbsp;%\u201370&nbsp;%<sup>2,8<\/sup><\/strong><\/p>\n\n\n\n<p><strong>NASH<\/strong><strong>: 25\u201330&nbsp;%<sup>5<\/sup><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">PERSPECTIVAS<\/h2>\n\n\n\n<p>Se espera que los \u00edndices de diabetes en todo el mundo se incrementen en alrededor del 55&nbsp;% antes de 2035, de acuerdo con la International Diabetes Federation, lo cual significa que la poblaci\u00f3n en riesgo de padecer NAFLD\/NASH se incrementar\u00e1 dr\u00e1sticamente durante las siguientes d\u00e9cadas.<sup>2,9<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">ENTRE LOS FACTORES DE RIESGO ESTABLECIDOS SE INCLUYEN<sup>2<\/sup><\/h2>\n\n\n\n<ul>\n<li>Variaci\u00f3n gen\u00e9tica vinculada a la prote\u00edna&nbsp;3 que contiene el dominio de fosfolipasa similar a la patatina (<em>PNPLA3<\/em><em>).<\/em><\/li>\n\n\n\n<li>Obesidad.<\/li>\n\n\n\n<li>Diabetes tipo&nbsp;2.<\/li>\n\n\n\n<li>Hipertensi\u00f3n.<\/li>\n\n\n\n<li>Resistencia a la insulina.<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Los niveles de aspartato aminotransferasa (AST) y alanina transaminasa (ALT).<\/li>\n\n\n\n<li>S\u00edndrome metab\u00f3lico (tres de las cinco caracter\u00edsticas):\n<ul>\n<li>Glucosa en ayunas alterada.<\/li>\n\n\n\n<li>Nivel elevado de triglic\u00e9ridos.<\/li>\n\n\n\n<li>Baja lipoprote\u00edna de alta densidad (HDL).<\/li>\n\n\n\n<li>Aumento de la circunferencia de la cintura.<\/li>\n\n\n\n<li>Hipertensi\u00f3n arterial.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">AFECCIONES ASOCIADAS CON NAFLD<sup>2<\/sup><\/h2>\n\n\n\n<ul>\n<li>Apnea del sue\u00f1o obstructiva.<\/li>\n\n\n\n<li>C\u00e1ncer colorrectal.<\/li>\n\n\n\n<li>Osteoporosis<\/li>\n\n\n\n<li>Psoriasis<\/li>\n<\/ul>\n\n\n\n<ul>\n<li>Endocrinopat\u00edas.<\/li>\n\n\n\n<li>Hipotiroidismo<\/li>\n\n\n\n<li>S\u00edndrome de ovario poliqu\u00edstico independientemente de la obesidad.<\/li>\n<\/ul>\n\n\n\n<p><a href=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/es\/que-es-nash\/como-se-diagnostica-nash\/\">\u00bfC\u00d3MO SE DIAGNOSTICA NASH?<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/es\/folletos-educativos\/\">EXPLORE NUESTROS FOLLETOS EDUCATIVOS<\/a><\/p>\n\n\n\n<p>References<\/p>\n\n\n\n<ol>\n<li>Machado M, Marques-Vidal P, Cortex-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery.&nbsp;<em>J Hepatol<\/em>. 2006;45(4):600-606.<\/li>\n\n\n\n<li>Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.&nbsp;<em>Hepatology<\/em>. 2018;67(1):328-357.<\/li>\n\n\n\n<li>Subichin M, Clanton J, Makuszewski M, Bohon A, Zografakis JG, Dan A. Liver disease in the morbidly obese: a review of 1000 consecutive patients undergoing weight loss surgery.&nbsp;<em>Surg Obes Relat Dis<\/em>. 2015;11(1):137-41.<\/li>\n\n\n\n<li>Dhir G,Cusi K. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.&nbsp;<em>J Investig Med<\/em>. 2018;66(1):7-10.<\/li>\n\n\n\n<li>Anstee QM1, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.&nbsp;<em>Nat Rev Gastroenterol Hepatol<\/em>. 2013;10(6):330-44.<\/li>\n\n\n\n<li>Organisation for Economic Co-operation and Development (OECD). Obesity Update 2017. https:\/\/www.oecd.org\/els\/health-systems\/Obesity-Update-2017.pdf. Published 2017. Accessed October 8, 2019.<\/li>\n\n\n\n<li>Kaiser AB, Zhang N, Van Der Pluijm W. Global prevalence of Type 2 diabetes over the next ten years.&nbsp;<em>Diabetes<\/em>. 2018;67(Suppl 1). https:\/\/diabetes.diabetesjournals.org\/content\/67\/Supplement_1\/202-LB. Accessed October 10, 2019.<\/li>\n\n\n\n<li>Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.&nbsp;<em>Diabetes Care<\/em>. 2017;40(3):419-430.<\/li>\n\n\n\n<li>Guariguata L, Whiting DR, Hambleton I, et al. Global estimates of diabetes prevalence for 2013 and projections for 2035.\u00a0<em>Diabetes Res Clin Pract<\/em>. 2014;103:137-149.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>PERSONAS CON OBESIDAD Tanto NASH como NAFLD tienen un alto predominio en las poblaciones que padecen obesidad, pero la cifras &#8230; <\/p>\n<p class=\"read-more-container\"><a title=\"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH?\" class=\"read-more button\" href=\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/#more-1196\" aria-label=\"More on \u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH?\">Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":1189,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"ub_ctt_via":"","footnotes":""},"featured_image_src":null,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease\" \/>\n<meta property=\"og:description\" content=\"PERSONAS CON OBESIDAD Tanto NASH como NAFLD tienen un alto predominio en las poblaciones que padecen obesidad, pero la cifras ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/\" \/>\n<meta property=\"og:site_name\" content=\"NASH Disease\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/obesity.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/\",\"url\":\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/\",\"name\":\"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease\",\"isPartOf\":{\"@id\":\"https:\/\/www.the-nash-education-program.com\/#website\"},\"datePublished\":\"2024-01-17T13:59:46+00:00\",\"dateModified\":\"2024-01-17T13:59:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.the-nash-education-program.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u00bfQu\u00e9 es NASH?\",\"item\":\"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.the-nash-education-program.com\/#website\",\"url\":\"https:\/\/www.the-nash-education-program.com\/\",\"name\":\"NASH Disease\",\"description\":\"The NASH Education Program\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.the-nash-education-program.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/","og_locale":"en_US","og_type":"article","og_title":"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease","og_description":"PERSONAS CON OBESIDAD Tanto NASH como NAFLD tienen un alto predominio en las poblaciones que padecen obesidad, pero la cifras ... Read more","og_url":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/","og_site_name":"NASH Disease","og_image":[{"url":"https:\/\/www.waybackmachinedownloader.com\/scraping\/files\/live\/the-nash-education-program.com_georgenjenga69_yahoo.com_zyrp7w0mtc\/wp-content\/uploads\/2018\/03\/obesity.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/","url":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/","name":"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH? - NASH Disease","isPartOf":{"@id":"https:\/\/www.the-nash-education-program.com\/#website"},"datePublished":"2024-01-17T13:59:46+00:00","dateModified":"2024-01-17T13:59:46+00:00","breadcrumb":{"@id":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/quienes-estan-en-riesgo-de-padecer-nash\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.the-nash-education-program.com\/"},{"@type":"ListItem","position":2,"name":"\u00bfQu\u00e9 es NASH?","item":"https:\/\/www.the-nash-education-program.com\/es\/que-es-nash\/"},{"@type":"ListItem","position":3,"name":"\u00bfQUI\u00c9NES EST\u00c1N EN RIESGO DE PADECER NASH?"}]},{"@type":"WebSite","@id":"https:\/\/www.the-nash-education-program.com\/#website","url":"https:\/\/www.the-nash-education-program.com\/","name":"NASH Disease","description":"The NASH Education Program","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.the-nash-education-program.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/1196"}],"collection":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/comments?post=1196"}],"version-history":[{"count":0,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/1196\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/pages\/1189"}],"wp:attachment":[{"href":"https:\/\/www.the-nash-education-program.com\/wp-json\/wp\/v2\/media?parent=1196"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}